Muscarinic receptor binding changes in postmortem Parkinson's disease

Caitlin McOmish; Geoff Pavey; Catriona McLean; Malcolm Horne; Brian Dean; Elizabeth Scarr

Journal article

Muscarinic receptor binding changes in postmortem Parkinson's disease

Caitlin McOmish, Geoff Pavey, Catriona McLean, Malcolm Horne, Brian Dean, Elizabeth Scarr

JOURNAL OF NEURAL TRANSMISSION | SPRINGER WIEN | Published : 2017

DOI: 10.1007/s00702-016-1629-z

Abstract

Parkinson's disease (PD) is a devastating disorder, affecting approximately 2% of people aged 60 and above. It is marked by progressive neurodegeneration that has long been known to impact dopaminergic cells and circuits, but more recently the acetylcholine system has also been implicated in the complex aetiology and symptomatology of the disease. While broad changes in cholinergic markers have been described, insight into the contribution of specific acetylcholine receptors is less clear. To address this important unknown, in this study we performed [3H] pirenzepine, [3H] 4DAMP, and [3H] AF-DX 384 in situ radioligand binding on postmortem tissues from Brodmann's area 6, 9, 46, and the cauda..

View full abstract

University of Melbourne Researchers

Brian Dean Author Florey Department of Neuroscience and Mental Health

Catriona McLean Author Florey Department of Neuroscience and Mental Health

Malcolm Horne Author Florey Department of Neuroscience and Mental Health

Related Projects (3)

Muscarinic receptors in the human brain: In health and in sickness

Schizophrenia is a severe mental illness, with sub-optimal treatment outcomes. New drugs are being designed to provide more effective treatm..

TUMOUR NECROSIS FACTOR SIGNALLING IN MOOD DISORDERS AND SCHIZOPHRENIA

Changes in inflammation-related pathways contribute to the symptoms of psychiatric disorders and tumour necrosis factor ? (TNF) is a protein..

The cause of psychiatric disease

The Applicant seeks to understand the causes of the schizophrenia, bipolar disorder and major depressive disorder, which affect over 20% of ..

Grants

Awarded by NHMRC

Awarded by Brain and Behavior Research Foundation

Awarded by ARC

Funding Acknowledgements

CEM was supported by an NHMRC overseas biomedical research fellowship (APP628906), a Brain and Behavior Research Foundation Young Investigator Award (19543), while these studies were being performed. BD is an NHMRC Senior Research Fellow (APP1002240). This work was supported in part by NHMRC Project Grants (APP1045619, APP628699, and APP1066144), the Victorian Government's Operational Infrastructure Support, and the Rebecca Cooper Medical Research Foundation. ES was supported by an ARC future fellowship (FT100100689). The funding sources were not involved in the study design; in the collection, the analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.